Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

EnhancerDB 2.0: a comprehensive cross-species enhancer atlas.

Molecular biology and evolution·2026

Same author

Circulating Apelin-13, β-catenin and bone mineral density in postmenopausal women.

Endocrine connections·2026

Same author

Electrochemically Assisted Synthesis of Covalent Organic Frameworks via In Situ Oxidation of Alcohol Monomers.

Journal of the American Chemical Society·2026

Same author

Clinical effects of surgical delay in older patients with intertrochanteric fractures: analysis from the National Inpatient Sample Database.

BMC geriatrics·2026

Same author

Pediatric GBS-myelitis overlap syndrome: Severe phenotype, treatment response, and neurological outcomes.

Brain & development·2026

Same author

A pH-responsive liposomal nanoplatform for reprogramming lactate metabolism and immunogenic activation in pancreatic cancer.

Biomaterials·2026

Search research articles

Related Experiment Video

Updated: May 28, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Neoantigen-based TCR-T therapy in solid tumors.

Wenjie Feng¹, Daichao Wu², Yukun Li¹

¹Tumor ImmunoMetabolism Institute (TIMI), The Affiliated Zhuzhou Hospital of Xiangya Medical College, Central South University, Zhuzhou, Hunan, P.R. China.

International Review of Cell and Molecular Biology

|May 26, 2026

Summary

T-cell receptor (TCR)-T cell therapy shows promise for solid tumors, offering advantages over CAR-T therapy. This review explores novel TCR targets and methods to enhance TCR-T cell therapy

Keywords:

Neoantigen Prediction algorithms Solid tumor TCR TCR-T therapy

More Related Videos

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Related Experiment Videos

Last Updated: May 28, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Area of Science:

Oncology
Immunology
Biotechnology

Background:

T-cell immunotherapy, including chimeric antigen receptor (CAR)-T and engineered T-cell receptor (TCR)-T cells, is a key cancer treatment strategy.
TCR-T cells offer advantages for solid tumors, recognizing intracellular and cell surface antigens with a lower risk of adverse effects due to physiological T cell activation.

Purpose of the Study:

To provide an overview of novel TCR-related cancer therapeutic targets.
To expand the application of TCR-T cell therapy in solid tumors.
To discuss challenges and solutions for improving TCR-T cell therapy safety and efficacy.

Main Methods:

Literature review of novel antigen and TCR identification methods.
Analysis of current challenges in TCR-T cell therapy.
Review of clinical research status and future directions.

Main Results:

TCR-T cells demonstrate potential for solid tumor treatment due to their antigen recognition capabilities and safety profile.
Novel methods for identifying antigens and TCRs are crucial for expanding therapeutic applications.
Addressing challenges in safety and efficacy is key to advancing TCR-T cell therapy.

Conclusions:

TCR-T cell therapy holds significant promise for solid tumor treatment.
Further research into novel targets and improved therapeutic strategies is essential.
Continued clinical investigation will drive the future development of TCR-T cell therapy.